Holmusk Funding, Investors & Competitors

Holmusk has raised $106M across 4 funding rounds, most recently a $30M strategic investment round in October 2023.

Last Holmusk funding round

$30M

Strategic investment · Oct 2023

Cumulative funding Holmusk raised

$106M

across 4 funding rounds

Key investors in Holmusk

  • Heritas Capital
  • Health Catalyst Capital
  • Veradigm
  • Novartis
  • Optum Ventures
  • Northwell Ventures
  • Capikris Foundation

Holmusk Overview

About Holmusk

Holmusk is a New York City-headquartered platform aggregating real-world evidence from behavioral health electronic health records for chronic disease management. The Holmusk Insights engine processes de-identified data from over 7 million patient lives across 200 providers in the US and UK. It supports pharmaceutical firms like Janssen in drug commercialization and clinicians at facilities like NYU Langone with treatment decision tools. Founded in 2015, Holmusk partners with payers including Aetna to advance evidence-based care in mental health.


Founded

2015

HQ

SingaporeSingapore

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Holmusk Funding History

Holmusk has raised a total of $106M across 4 funding rounds.

Holmusk's first fundraising round was a $10M seed round in September 2018. The most recent completed round was a $30M strategic investment round in October 2023.

Holmusk funding rounds

Holmusk funding rounds
DateStageInvestorsRaisedDeal Summary
Oct 2023Strategic investmentVeradigm (lead)$30MHolmusk is a global behavioral health real-world evidence and data analytics company that operates the NeuroBlu Database, a leading source of real-world clinical data for the behavioral health industry. The company combines this database with AI-powered analytics and digital solutions to advance evidence generation, research, and care outcomes in behavioral health. Headquartered in New York with additional offices in Singapore and elsewhere, Holmusk focuses on curating and enhancing behavioral health data to address global mental health challenges exacerbated by the COVID-19 pandemic. In early 2023, Veradigm (formerly Allscripts Healthcare Solutions) led Holmusk's $45 million Series B financing round, with participation from existing investors including Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), and Northwell Holdings. This investment supports Holmusk's rapid expansion of the NeuroBlu Database and related offerings. Later, on October 2, 2023, Veradigm closed a $30 million strategic investment in Holmusk (reported as approximately $29.999978 million in some filings), marking a new phase of collaboration that includes adding millions of de-identified behavioral health patient records from Veradigm to NeuroBlu. The partnership enhances NeuroBlu's scale, enabling more advanced research cohorts and insights into behavioral healthcare delivery for biopharma, health insurers, and health systems. The collaboration aims to deepen impact in behavioral health through data-driven evidence and innovation.
Jan 2023Series BVeradigm (lead); Heritas Capital; Northwell Ventures; Novartis; Health Catalyst Capital$45MHolmusk is a global behavioral health real-world evidence and data analytics company offering the NeuroBlu Database, a leading source of real-world clinical data for the behavioral health industry. The company raised a $45 million Series B financing round announced in January 2023, led by Veradigm (formerly Allscripts), with participation from Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), Northwell Holdings (Northwell Ventures), and other previous investors. The funds are intended to support rapid expansion of the NeuroBlu Database and curation of behavioral health data to build the world's largest platform for the sector, alongside a data partnership with Veradigm to add de-identified patient data cohorts. Subsequent to the Series B, Veradigm made an additional strategic investment of approximately $30 million (reported as $29.999978M or $30M) in Holmusk around October 1-3, 2023, labeled as Series B - II in some sources, further strengthening their collaboration by contributing millions of behavioral health patient records to NeuroBlu. This builds on prior rounds including a $21.5 million Series A in May 2020 and an undisclosed amount in December 2021 from Northwell Holdings, Optum Ventures, Health Catalyst Capital, and Heritas Capital, bringing total funding to $106.3M over 9 rounds as of October 2023. Holmusk focuses on improving mental and behavioral health outcomes through quality real-world data, evidence generation, and analytics for biopharma, health insurance, and health systems. Partnerships like with Metrocare Services in February 2023 aim to develop tools for better care outcomes.
May 2020Series AHealth Catalyst Capital (lead); Optum Ventures (lead); Heritas Capital$22MHolmusk is a data science and health technology company founded in 2015 and headquartered in Singapore with offices in New York City, London, Shanghai, and Durham, North Carolina. The company builds a Real-World Evidence (RWE) platform focused on behavioral health and chronic diseases, leveraging longitudinal data from mental health institutions across the United States spanning over 20 years. In 2016, Holmusk acquired MindLinc, an Electronic Health Record (EHR) system focused on behavioral health, from Duke University School of Medicine, enabling the company to access this extensive historical dataset. The company's flagship product, NeuroBlu, contains data from more than half a million patients with in excess of 20 million encounters. On May 18, 2020, Holmusk closed a Series A funding round of $21.5 million led by Optum Ventures and Health Catalyst Capital, with participation from existing investors Heritas Capital and other individuals. Dr. Vijay Barathan from Optum Ventures and Charles Boorady from Health Catalyst Capital joined the company's Board of Directors as part of the round. The funding was designated to expand Holmusk's U.S. operations in New York City and to invest in its proprietary technology platform to harness and analyze real-world data to accelerate drug development and data-driven medicine. Prior to this Series A, the company had raised $9.8 million in a seed round in September 2018. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum and was selected as part of the Innovations in Healthcare's 2020 Innovator Cohort, validating its evidence-based approach to improving care for people suffering from behavioral health disorders.
Sep 2018SeedHeritas Capital; Capikris Foundation$10MHolmusk, a Singapore-based digital health and data analytics company, raised US$9.75 million in a pre-Series A funding round on September 25, 2018, led by Heritas Venture Fund with participation from new and existing investors. The company leverages technology to accelerate research and improve outcomes for chronic diseases and behavioral health disorders, collaborating with pharma and healthcare providers for predictive algorithms and personalized medicine insights. Holmusk acquired MindLinc in 2016, gaining one of the largest behavioral health databases from Duke University School of Medicine, and was developing MindLinc 2.0 with predictive disease models. The funding provided a runway to expand aggressively in the US and Europe, focusing on core segments of chronic disease management and behavioral health.

Who has invested in Holmusk?

7 investors have backed Holmusk across its funding rounds, including Heritas Capital, Health Catalyst Capital, Veradigm, Novartis, Optum Ventures and Northwell Ventures.

Lead investors include Veradigm, Health Catalyst Capital and Optum Ventures.


Holmusk Investors

Investors in Holmusk by funding rounds participated
InvestorHQRoundsRoleFirst check
Heritas CapitalSingaporeSingapore3ParticipantSep 2018
Health Catalyst CapitalUnited StatesNew York City, NY2LeadMay 2020
VeradigmUnited StatesChicago, IL2LeadJan 2023
Northwell VenturesUnited StatesNew York City, NY1ParticipantJan 2023
NovartisSwitzerlandBasel1ParticipantJan 2023

This data is available for Pro users. Sign up to see all 7 Holmusk investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Holmusk

Holmusk has acquired 2 companies to date.

Last acquisition by Holmusk was on April 27th 2021. Holmusk acquired Otsuka Health Solutions for undisclosed valuation.


Latest Acquisitions by Holmusk

Otsuka Health Solutions
MindLinc
Description
Otsuka Health Solutions is a provider of digital therapeutics and predictive analytics for mental health. Princeton-headquartered, it develops platforms like Rejoyn for treatment-resistant depression using FDA-cleared software. The company collaborates with pharmaceutical divisions on patient monitoring tools.
MindLinc is a behavioral health EHR system for psychiatric practices and clinics. Headquartered in Raleigh, North Carolina, it manages patient records, billing, outcomes tracking, and research data. The cloud-based platform integrates telehealth, regulatory reporting, and evidence-based protocols for over 200 providers nationwide.
HQ CountryUnited KingdomUnited States
HQ City
London
Durham, NC
Deal Date27 Apr 202123 Mar 2016
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Holmusk acquisitions and their M&A valuation multiples.

Start Free Trial

Holmusk Competitors

Holmusk competitors include listed companies like TALI Digital, Evolent Health and Talkspace, and private ones like Thrive Global, Biopeak and Slingshot AI.

Public and private companies comparable to Holmusk
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
TALI DigitalAustraliaAustraliaPublicly listed$166K($2M)$3M-
Thrive GlobalUnited StatesNew York City, NYPrivate--$700M-
Evolent HealthUnited StatesUnited StatesPublicly listed$1.9B($365M)$415M0.5x
TalkspaceUnited StatesUnited StatesPublicly listed$229M$6M$871M3.4x
BiopeakIndiaBangalorePrivate$2M-$250M125.0x
Slingshot AIUnited StatesSan Francisco, CAPrivate$10M-$220M22.0x

Holmusk Public Comps

Holmusk is still privately-owned, but its public comps include Humana Inc., IQVIA, Revvity, Solventum, Tempus AI, ICON plc, Caris Life Sciences, Hinge Health, Hims and Doximity.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Humana Inc.$130B$3B0.4x0.3x17.8x16.6x
IQVIA$16B$3.4B3.6x3.4x17.2x14.8x
Revvity$2.9B$735M6.5x6.6x25.4x21.0x
Solventum$8.3B$2.5B2.4x2.4x7.8x8.9x
Tempus AI$1.3B($131M)12.0x10.1x(116.0x)346.0x
ICON plc$8.3B$816M1.9x1.9x19.2x11.3x
Caris Life Sciences$812M($5M)10.3x8.7x(1640.5x)49.4x
Hinge Health$588M($522M)12.3x9.3x(13.9x)34.6x

This data is available for Pro users. Sign up to see all Holmusk competitors and their valuation data.

Start Free Trial

Common questions about Holmusk

When was Holmusk founded?Holmusk was founded in 2015.
Where is Holmusk headquartered?Holmusk is headquartered in Singapore, Singapore.
Is Holmusk publicly listed?No, Holmusk is a private, VC-backed company.
How much funding has Holmusk raised?Holmusk has raised $106M across 4 funding rounds.
What was Holmusk's last funding round?Holmusk's last funding round was a $30M strategic investment round in October 2023, led by Veradigm.
Who are Holmusk's investors?Holmusk's investors include Heritas Capital, Health Catalyst Capital, Veradigm, Northwell Ventures, Novartis, Capikris Foundation and Optum Ventures.
Which companies are comparable to Holmusk?Companies comparable to Holmusk include TALI Digital, Thrive Global, Evolent Health, Talkspace, Biopeak and Slingshot AI.
How many companies has Holmusk acquired?Holmusk has acquired 2 companies, including Otsuka Health Solutions and MindLinc.

See companies similar to Holmusk

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial